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Abstract
Antibiotics are potent pharmacological weapons against bacterial infections; however, the growing antibiotic resistance of microor-
ganisms is compromising the efficacy of the currently available pharmacotherapies. Even though antimicrobial resistance is not a
new problem, antibiotic development has failed to match the growth of resistant pathogens and hence, it is highly critical to
discover new anti-infective drugs with novel mechanisms of action which will help reducing the burden of multidrug-resistant
microorganisms. Protein–protein interactions (PPIs) are involved in a myriad of vital cellular processes and have become an attrac-
tive target to treat diseases. Therefore, targeting PPI networks in bacteria may offer a new and unconventional point of intervention
to develop novel anti-infective drugs which can combat the ever-increasing rate of multidrug-resistant bacteria. This review de-
scribes the progress achieved towards the discovery of molecules that disrupt PPI systems in bacteria for which inhibitors have been
identified and whose targets could represent an alternative lead discovery strategy to obtain new anti-infective molecules.
Introduction
Bacterial infections are not only one of the most frequent
diseases in humans and livestock, but also one of the top ten
causes of death according to the World Health Organization [1].
The serendipitous discovery of penicillin and its introduction
into the clinic in the first half of the 20th century gave rise to
the “Golden Age” of antibiotics discovery and have unquestion-
ably represented one of the most important achievements in
medicine. Unfortunately, since their use is intrinsically linked to
the appearance of resistance, threatening antibiotic-resistant
bacteria levels are being observed, compromising the efficacy
of nearly all available antibiotics to cure infectious diseases
[2-4].
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The rise in the percentage of antibiotic-insensitive strains, the
steady decline in the number of new antibacterial drugs and the
insufficient investment in antimicrobial research and develop-
ment (R&D) by the major pharmaceutical companies have led
to a global health crisis in which the prospect of a future with-
out a safe and effective anti-infective compound is a very real
and alarming possibility [5,6]. Consequently, new antibacterial
drugs and treatment strategies are urgently needed to tackle the
increasing multidrug-resistance in bacteria [7].
To further accelerate antibiotics development numerous ap-
proaches have been put in place. For example, the WHO
recently published a list of global priority antibiotic-resistant
bacteria to help prioritizing the research and development of
new and effective antibiotic treatments [8]. In this list the
pathogens were ranked in three priority levels according to the
species and type of resistance:
1. Priority 1 – Critical:
• Acinetobacter baumannii, carbapenem-resistant
• Pseudomonas aeruginosa, carbapenem-resistant
• Enterobacteriaceae, carbapenem-resistant, 3rd genera-
tion cephalosporin-resistant
2. Priority 2 – High:
• Enterococcus faecium, vancomycin-resistant
• Staphylococcus aureus, methicillin-resistant, vanco-
mycin intermediate and resistant
• Helicobacter pylori, clarithromycin-resistant
• Campylobacter, fluoroquinolone-resistant
• Salmonella spp., fluoroquinolone-resistant
• Neisseria gonorrhoeae, 3rd generation cephalosporinre-
sistant, fluoroquinolone-resistant
3. Priority 3 – Medium:
• Streptococcus pneumoniae, penicillin-non-susceptible
• Haemophilus influenzae, ampicillin-resistant
• Shigella spp., fluoroquinolone-resistant
Given the prevalence of antibacterial drug-resistant pathogens,
one viable and promising strategy to combat these multidrug-
resistant bacteria is the development of antibiotic therapies with
novel unconventional targets [9], such as protein–protein inter-
actions [10,11].
This review covers the recent medicinal chemistry efforts
towards the discovery of antibacterial molecules that disrupt
protein–protein interactions (PPIs) by interacting directly to the
protein–protein binding interface in both Gram-negative and
Gram-positive microorganisms. In order to encourage prospec-
tive drug discovery endeavours in this field, this study focuses
on four examples of bacterial PPIs for which inhibitors with
promising activities have been reported. For each of the targets
the structural features of the ligands, the discovery strategy, the
characterization assay, the biological activity, and, if applicable,
the SAR are discussed.
Review
Protein–protein interactions
Due to the fact that protein–protein interactions (PPIs) play a
pivotal role in many cellular processes, they have increasingly
become an attractive target over the past two decades [12-14].
PPIs are challenging targets because of their flat, large and
hydrophobic binding surface, in comparison with the well-
defined binding sites of more classical targets such as GPCRs,
enzymes or ion channels (Figure 1). Moreover, PPIs, unlike the
previous examples, do not have a small natural ligand which
can be used as a lead in a standard drug development
programme [15,16]. Despite the binding surfaces being large, it
is well known that not all the amino acid residues at the inter-
face contribute equally to the binding, but in fact there are focal
points (i.e., hot spots or hot segments) that contribute to the
majority of the binding energy [17,18]. Targeting these “drug-
gable” sites can therefore be used for the rational design of new
therapeutic compounds that can disrupt those critical interac-
tions. However, their identification requires detailed structure
elucidation, which in the end makes the design of an effective
PPI modulator both difficult and challenging [19-22]. PPI
modulation can be achieved through two opposite but comple-
mentary approaches: stabilization or inhibition (Figure 1). Al-
though so far the vast majority of protein–protein interaction
modulators execute their activity through inhibition, stabiliza-
tion of specific protein complexes could also be therapeutically
beneficial [23,24].
Even though historically PPIs have been considered to be
“undruggable”, recent remarkable medicinal chemistry efforts,
mainly due to the development and implementation of more
sophisticated screening methods and synthetic procedures, have
led to the identification and clinical development of chemical
entities that disrupt protein–protein interactions [15,25,26].
A selection of a few PPI modulators that have recently been ap-
proved or reached clinical validation can be found in Figure 2.
If we analyze their mechanism of action, nearly all of them are
currently being investigated as oncological treatments. For ex-
ample, navitoclax (1, Figure 2), a Bcl-2/Bcl-XL inhibitor de-
veloped by Abbot Laboratories is currently in phase II for the
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Figure 1: Illustration of a PPI modulator (stabilizer or inhibitor) vs a traditional drug target.
treatment of several types of cancers [27]. Idasanutlin (2,
Figure 2) from Hoffmann-La Roche, targets the extensively
studied interaction between MDM2/p53 and is currently in
phase III for the treatment of refractory acute myeloid leukemia
in combination with cytarabine [28]. LCL-161 (3, Figure 2), an
inhibitor of the interaction between Smac (second mitochon-
dria-derived activator of caspases) and IAP (inhibitor of apopto-
sis proteins) developed by Novartis, has recently entered phase
II for the treatment of leukaemia [29]. Another example is the
inhibitor of the BET (bromodomain and extra terminal) moli-
bresib (4, Figure 2), developed by GSK and currently in phase I
for the treatment of several carcinomas [30]. It is also worth
highlighting two PPI inhibitors that have recently been ap-
proved: lifitegrast (5, Figure 2) is an anti-inflammatory integrin
antagonist that disrupts the LFA-1/ICAM-1 interaction used for
the treatment of dry eye disease [31,32], and tirofiban (6,
Figure 2), a platelet glycoprotein IIb/IIIa inhibitor indicated in
acute coronary syndrome [33]. In addition to small molecules,
natural products have been shown to be able to modulate pro-
tein–protein interactions and have validated PPI stabilization as
a biological target. One of the most prominent examples of PPI-
stabilizing natural products that are currently used in the treat-
ments of human diseases is rapamycin (7, Figure 2), an
immunosuppressant that inhibits the protein kinase TOR (target
of rapamycin) [34]. This natural product, isolated from Strepto-
myces hygroscopicus, was one of the first protein–protein inter-
action stabilizers reported: it first binds to its receptor (i.e.,
FKBP12) with high affinity, after which the FKBP12-
rapamycin complex will associate with TOR resulting in inhibi-
tion of the catalytic activity of the enzyme [23].
All these drug discovery successes have validated PPIs as a
target and, in conjunction with the elucidation and reconstruc-
tion of protein–protein interaction networks in bacteria, have
paved the way towards the development of novel and promis-
ing inhibitors of PPIs which may find application as anti-infec-
tive therapies.
Protein–protein interactions in bacteria
Like in eukaryotes, protein–protein interactions are essential in
prokaryotic cells in which they also have a central role. They
coordinate many bacterial physiological processes such as regu-
lation of gene expression, DNA replication, signal transduction,
virulence, etc. and therefore represent potential fruitful targets
for antibacterial drug discovery.
Recently, scientific efforts have helped towards the under-
standing and the deciphering of the protein-interaction networks
(PINs) that forge the bacterial interactome [35]. However,
despite the potential of these bacterial PPI maps, they have only
been studied in detail in a few microorganisms including
Escherichia coli (one of the best-studied model organisms in
this field) [36-39], Mycobacterium tuberculosis [40], Heli-
cobacter pylori [41], Pseudomonas aeruginosa [42], Campy-
lobacter jejuni [43], Treponema pallidum [44], the cyanobac-
terium Synechocystis spp. [45], Mesorhizobium loti [46] and
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Figure 2: Examples of protein–protein interaction modulators in clinical trials or in clinical use.
Mycoplasma pneumoniae [47]. Furthermore, partial PINs for
Bacillus subtilis [48] and Streptococcus pneumoniae [49] have
been reported recently, and many more are near completion
[50].
These hundreds of thousands of known interactions, and those
which are yet to be discovered, have been and will be essential
for identifying potential points of intervention in clinically rele-
vant pathogens that can serve as drug targets for antibacterial
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therapy. There are several reasons that support this argument:
they are essential for not only the growth but the reproduction
of the cells, they are conserved across many strains of
pathogens and, most importantly, they are specific to the
prokaryotic kingdom, meaning that either these interactions are
non-existent or substantially different from their corresponding
processes in eukaryotic cells [51].
Four examples of protein–protein interaction systems in
bacteria for which inhibitors have been discovered and that
could represent an alternative lead-discovery strategy to obtain
new antimicrobial molecules are presented below.
β-Sliding clamp
Sliding clamps are prokaryotic ring-shaped proteins that secure
DNA polymerases to the DNA template and slide along the
double helix, enabling enzyme activity at a specific region of
the DNA and increasing the rapid and processive DNA synthe-
sis [52-54]. The β-clamp interacts with many different proteins
such as several polymerases (e.g. I, II, III, IV, V and DnaE) and
other proteins involved in DNA replication including DNA
ligase and the replication regulatory protein Hda, all of which
contain the conserved binding pentapeptide motif QL(S/D)LF
(8, Figure 3) [55,56].
There are several reasons that make the bacterial clamp a prom-
ising and attractive target for the development of new antibiot-
ics: it is essential for DNA replication and repair, it is highly
conserved across the different bacterial pathogens and, most im-
portantly from a drug discovery perspective, its structure differs
significantly from the eukaryotic equivalent clamp (PCNA,
proliferating cell nuclear activity) [51,57].
O’Donnell et al. first identified the structure of an inhibitor of
the E. coli sliding clamp (ECSC) [58]. In the search for a mole-
cule that binds to the peptide-binding pocket of the β-clamp,
they carried out a fluorescence anisotropy titration screening
of the Rockefeller University chemical library containing
30,600 polar organic compounds which led to the discovery of
RU7 (9, Figure 3) with an inhibition constant of 10 μM. Pleas-
ingly, it was also found that RU7 selectively disrupts the E. coli
β-clamp without affecting its eukaryotic counterpart in Saccha-
romyces cerevisiae. In this same study, the co-crystal structure
of RU7 with the sliding clamp revealed that the inhibitor occu-
pies the deepest subsite (i.e., 1) of the two subsites that form the
binding pocket (Figure 4) [58,59].
Utilizing a virtual screening of two different databases (i.e., the
National Cancer Institute [60] and an in-house collection of
32,000 compounds), Wijfells et al. were able to identify a
small-molecule mimic of the des-amino-Leu-Phe (dLF) compo-
nent of the ECSC 10 (Figure 3), which displayed an IC50 in the
low micromolar range (IC50 = 40 μM). X-ray crystallography
studies revealed that this biphenyl oxime derivative 10 also
occupies subsite I of the β-clamp [61].
In 2014, the Zenobia’s First Pass Screen fragment library con-
taining more than 350 fragments was screened by X-ray
crystallography leading to the identification of four fragment
hits. In an attempt to improve their binding affinities, another
library was searched for compounds displaying similarity to
these initial hits. After a docking-based screening followed by a
fluorescence polarization (FP) assay of the selected candidates,
the substituted tetrahydrocarbazole 11 (Figure 3) was found to
not only completely occupy E. coli SC subsite I with the highest
affinity (IC50 = 115 μM) and to inhibit in vitro DNA replica-
tion, but also to have antibacterial activity against several
Gram-positive and Gram-negative pathogens, namely Bacillus
subtilis, Staphylococcus aureus, Escherichia coli and Acineto-
bacter baylyi with MICs ranging from 39 to 78 μM [62]. A year
later, further SAR investigations from the same research group
led to the identification of another tetrahydrocarbazole deriva-
tive 12 (Figure 3) which displayed a >4-fold increase in its
affinity for E. coli SC [63].
Recent evidence suggests that non-steroidal anti-inflammatory
drugs (NSAIDs) have antimicrobial activity. Oakley et al.
studied the E. coli β-clamp binding affinity of commercially
available NSAIDs with the help of a FP competition assay. Of
the twenty compounds evaluated, five showed Ki values in the
high micromolar range, but only vedaprofen, bromfenac and
carprofen (13–15, Figure 3) displayed the strongest effects
(Ki < 300 μM) [64]. Similarly to the preliminary study by Yin et
al. [62] the antibacterial activity of the selected NSAIDs was
determined on four clinically relevant species, two Gram-nega-
tive bacteria (E. coli and A. baylyi) and two Gram-positive
(S. aureus and B. subtilis). In opposition to Yin’s studies, the
latter species showed higher susceptibility than the Gram-nega-
tive bacteria with minimal inhibitory concentrations as low as
44 μg/mL in the case of vedaprofen (13). Again, and in agree-
ment with previous studies, the compounds that most potently
inhibited E. coli β-clamp binding also showed the highest level
of antibacterial activity, supporting the correlation between
inhibition of the sliding clamp and the antibacterial effects.
In addition to small molecules, peptides have also been investi-
gated as disruptors of protein–protein interactions in the sliding
clamp.
A structure-based approach, using the natural pentapeptide
QL(S/D)LF (8, Figure 3) as a template, led to the identification
of the short peptide P6 (16, Figure 5) with enhanced affinity for
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Figure 3: Small-molecule inhibitors of PPIs in the β-sliding clamp.
the β-clamp (IC50 = 1.12 μM, measured by surface plasmon
resonance). This acetylated peptide was used as a lead and
further modified at the second position, where the leucine
residue was replaced by a cyclohexyl-L-alanyl group (Cha), and
also on the terminal phenylalanine benzyl ring, in which two
chlorine atoms where incorporated in the benzene ring to
achieve P14 (17, Figure 5) with a 15-fold increase of its binding
affinity for the sliding clamp and reaching the 10−8 M range
(IC50 = 0.077 μM) [65].
Recently, Løbner-Olesen and co-workers screened a library of
peptides for their ability to disrupt PPIs in the β-sliding clamp
of Staphylococcus aureus. In this elegant study, from a library
of 900,000 cyclic peptides, which was intracellularly generated
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Figure 4: Crystal structure of the RU7 (9)-sliding clamp complex (PDB
code 3D1G; adapted from Georgescu et al. [58]). Essential residues
R152, M362, S346 and R246 are highlighted (sticks).
using the split-intein circular ligation of peptides and proteins
(SICLOPPS) technology [66], three hits, peptides III-5, III-6
and III-7 (18–20, Figure 5), were identified to be able to disrupt
the DnaN–DnaN (β-clamp–β-clamp) interaction. Interestingly,
III-5 (18) and III-6 (19) were able to inhibit the growth of
Staphylococcus aureus with MIC values of approximately
50 μg/mL while their linear counterparts displayed no activity
[67].
Historically, natural products have been one of the most fruitful
sources to obtain antibacterial lead compounds [5,68,69]. Grise-
limycin, a cyclic depsidecapeptide isolated from Streptomyces
sp., was discovered fifty years ago, nonetheless, due to its poor
pharmacokinetic properties and the availability of other drugs
such as rifampicin, the optimization programme was aban-
doned [70]. Recently, the interest in neglected antibiotics with
anti-tuberculosis potential resurged and led to further optimiza-
tion and development studies around the griselimycin structure
(21, Figure 5) [71]. Müller et al. discovered that griselimycin
and its metabolically more stable analogues (methyl-grise-
limycin, MGM, 22 and cyclohexyl-griselimycin, CGM, 23)
were active against M. tuberculosis in the low micromolar range
with MICs of 1, 0.6 and 0.06 μg/mL, respectively. To charac-
terize the target protein of griselimycins, surface plasmon reso-
nance (SPR) was used, analysis that demonstrated that they
bound with high affinity to the sliding clamps of M. tuberculo-
sis (Kd ranging from 1.0 × 10−10 M to 2.0 × 10−10 M). Encour-
agingly, no binding was detected between griselimycins and the
human sliding clamp, and, hence, exhibiting an excellent selec-
tivity profile. Crystal structures revealed that GM (21) and
CGM (23) bind to a hydrophobic pocket between domains II
and III, the protein–protein interaction site responsible for the
recruitment of DNA enzymes by the sliding clamp, and there-
fore promisingly validating the sliding clamp as a feasible anti-
bacterial target.
Single-stranded DNA-binding protein (SSB)
SSB is a class of proteins that coordinates fundamental cell pro-
cesses including DNA replication, recombination and repair,
and is, consequently, vital for cell survival. In addition, it also
mediates the binding to more than fourteen genome mainte-
nance proteins of the SSB interactome [72]. This latter activity
enables SSB to act as a conserved hub of proteins which
recruits their binding partners (e.g., exonuclease I, the DNA
primase DnaG and the DNA helicase PriA) to their site of
action [73].
Similarly to the aforementioned sliding clamp, the structural
arrangement of most bacterial SSBs differs significantly to its
homolog in eukaryotic cells (replication protein A, RPA) [74].
This dissimilarity could be beneficial from a drug discovery
perspective because it would enable selective targeting of the
bacterial interactome without impacting the eukaryotic cell pro-
cesses.
Keck and co-workers identified four small molecules that
disrupt the Escherichia coli SSB interaction with one of its
well-studied binding partners, exonuclease I (ExoI) [75]. The
screening by means of a high-throughput fluorescence polariza-
tion assay of 50,400 compounds from the Chemical Diversity,
Maybridge and Chembridge chemical libraries, and subsequent
dose-dependent evaluation of the disruption of the SSB/ExoI
complex, led to the discovery of four inhibitors, CFAM, BCBP,
BOTP and MPTA (24–27, Figure 6), with IC50 values ranging
from 8–80 μM. Afterwards, the scientists were able to success-
fully obtain the crystal structures of the complexes of ExoI with
both CFAM (24) and BCBP (25). From the crystallography
studies it was revealed that, even though both compounds bind
to the B site of ExoI, only CFAM (24) is able to interact with
the crucial residues in the basic ridge which are known to be
essential for the in vitro complex formation of ExoI with SSB
[73], a finding that supports the low IC50 value exhibited by this
molecule. Remarkably, these four compounds were also able to
disrupt the complex formation of SSB with some other binding
partners such as the DNA helicases RecQ and PriA but, unfor-
tunately, less potently.
In an attempt to prove the hypothesis that direct targeting of
PPIs, particularly SSB, could be an effective strategy for the de-
velopment of novel broad-spectrum antibacterial agents, the
colony formation evaluation of three of the previously
mentioned hits (namely 24, 25 and 27) was assessed against a
panel of bacterial strains that included Gram-positive microor-
ganisms Listeria monocytogenes, Staphylococcus aureus,
Mycobacterium smegmatis, Mycobacterium tuberculosis,
Mycobacterium avium paratuberculosis and Mycobacterium
bovis, and Gram-negative pathogens Escherichia coli (wt and
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Figure 5: Peptidic inhibitors of PPIs in the sliding clamp.
imp4213), Bacillus subtilis, Neisseria gonorrhoeae, Neisseria
meningitidis and Neisseria lactamica [76]. As a result, the com-
pounds were able to successfully inhibit the growth of some of
the bacteria tested. The authors also determined the growth
suppressive effects on model Gram-positive (B. subtilis) and
Gram-negative (E. coli imp4213) bacteria. The MIC values
against B. subtilis were found to be 40, 11, 16 μM for CFAM,
BCBP and MPTA, respectively, while the MIC values against
the membrane-compromised E. coli were found to be 36, 62 and
10 μM, respectively.
High-throughput screening initiatives have gained popularity in
the past two decades and have become the prevailing approach
to identify leads in medicinal chemistry research [77,78]. How-
ever, due to the intrinsic features of PPIs, these are not
amenable to the HTS approaches used to identify small mole-
cules which will typically target enzymes (e.g., kinases and
proteases) or extracellular receptors [79].
Recently, a HTS strategy to identify inhibitors of the Klebsiella
pneumonia SSB PPI was reported. Starting from a library of
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Figure 6: SSB protein–protein interaction inhibitors identified by HTS.
Figure 7: SSB protein–protein interaction inhibitors identified by FBDD.
more than 72,000 compounds from Life Chemicals Inc.
(Munich, Germany), nine selective inhibitors of the SSB/PriA
interaction with IC50 values of <40 μM were identified by or-
thogonal fluorescence polarization assays. Of these nine initial
hits, two were observed to interact with PriA by thermal stabili-
sation in a differential scanning fluorimetry (DSF) assay [80].
Regrettably, no data was presented on the chemical structures of
these compounds or the antibacterial activity. Nevertheless, this
study reinforces the usefulness of integrating biophysical tech-
niques with HTS approaches in order to detect and investigate
SSB protein–protein interactions in bacterial systems.
In the same year, Oakley et al. implemented a fragment-based
drug discovery (FBDD) approach in order to identify disruptors
to the interaction of SSB with another of its partners, the DNA
primase DnaG [81]. In this study, a SPR competition assay
and a saturation-transfer difference NMR (STD-NMR)
led to the identification of thirty fragments. Subsequent
2D-15N–1H HSQC NMR returned four fragment hits 28–31
(Figure 7), with binding affinities, determined by NMR titra-
tion, in the low millimolar range.
Of all of the fragments, tetrazole 31 was chosen for further opti-
mization due to its physicochemical properties and its potential
for fragment growth. After virtual screening and binding
studies by STD-NMR studies, the authors were able to find
tetrazole 32 (Figure 7) which had a three-fold improved affinity
(Kd = 1.3 mM) compared to the initial hit 31. Later, the ZINC
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2890
Figure 8: Examples of molecules that disrupt the ZipA/FtsZ interaction.
database [82] was searched for structurally similar compounds
leading to the identification of the meta-substituted tetrazole 33
(Figure 7), which was found to have a similar dissociation con-
stant. Moreover, in order to predict the orientation of the frag-
ments in the binding site, molecular docking of 33 to DnaG was
predicted.
Finally, the fragments were also assessed against other SSB
partner proteins by means of STD-NMR. Although the affinity
values were not determined, all of them were satisfactorily
found to bind to E. coli PriA, E. coli RNAse HI and the
χ subunit of E. coli and A. Baumannii DNA polymerase III, and
thus represent promising leads in the search for PPI inhibitors in
bacteria.
Filamenting temperature-sensitive protein Z
(FtsZ)
FtsZ is a prokaryotic tubulin-like protein which plays a crucial
role in cell division in both Gram-positive and Gram-negative
bacteria [83]. This protein polymerizes into a ring structure (the
Z-ring) early at the division site and operates as a focal point for
the assembly of the other division proteins [84].
There are several advantages of cell-division proteins as an anti-
bacterial target: first, their intrinsic characteristics and essen-
tiality for the multiplication and viability of bacteria, and
second, they are highly conserved in many bacterial species
[85].
Various studies have shown that Z interaction protein A (ZipA)
is one of the essential components that stabilize the Z-ring for-
mation and that it binds to FtsZ with high affinity. The interac-
tion between FtsZ and ZipA is essential for cell division in
E. coli and other Gram-negative bacteria, and therefore, it has
been suggested that disruption of the ZipA/FtsZ interaction can
be exploited to develop potential antibacterial molecules
[83,86].
The development of a small-molecule antibiotic that targeted
the ZipA/FtsZ protein–protein interaction was first investigated
by scientists at Wyeth Research. In this study, a fluorescence
polarization-based high-throughput screening of 250,000 corpo-
rate compounds led to the identification of pyridylpyrimidine 34
(Figure 8), which was shown to be the most potent with a Ki of
12 μM as measured by a FP competition assay [87]. Kenny et
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al. succeeded in obtaining a crystal structure of 34 bound to
ZipA which provided detailed knowledge of the basis of the
binding mode. Interestingly, it was found that, although 34
occupies only half of the ZipA/FtsZ binding pocket, the phenyl,
the pyridine and the pyrimidine rings make critical hydro-
phobic interactions with residues in the shallow groove of the
pocket [87].
Nearly simultaneously, the same group reported the SAR
studies of a family of biphenylindole derivatives as inhibitors of
the same PPI. A structure-based design built on the indolo-
quinolizinone 35 (Figure 8), afforded the chimeric molecule
indole 36 (Figure 8) as an inhibitor of the ZipA/FtsZ interac-
tion with an improved, but still modest, IC50 of 192 μM. The
antibacterial activity of all the target compounds was also eval-
uated against a panel of microorganisms which included Gram-
positive pathogens Staphylococcus aureus, Streptococcus pneu-
moniae, Bacillus subtilis, Enterococcus faecalis and the Gram-
negative bacterium Escherichia coli (wt and an outer mem-
brane permeable strain). Gratifyingly, the antibacterial
screening showed that improved IC50 values correlated with im-
proved minimal inhibitory concentrations and that Gram-posi-
tive microorganisms are more susceptible, likely due to the
inability of molecules to permeate the outer membrane of
Gram-negative pathogens [88].
In a follow-up study, a combinatorial synthesis approach was
utilized to generate a library of small molecules whose inhibi-
tion properties were measured by a fluorescence polarization
competition assay [89]. Derivatization of the indole nitrogen
atom of lead compound 36 (Figure 8) returned the interesting
indole analogue 37 (Figure 8). The authors then confirmed that
the compounds were binding to the E. coli Zip A in the FtsZ
binding site by means of 2D-HSQC NMR experiments and later
submitted the selected compounds to cell division inhibition
assays and MIC determination against a broad panel of
bacterial strains which included S. aureus, B. subtilis, S. pneu-
moniae, H. influenzae, M. catarrhalis, and E. coli (imp). Unfor-
tunately, the most active compound, indole 37, exhibited an
IC50 = 296 μM and a dissociation constant of 105 μM which
undoubtedly make it a too weak inhibitor. Excitingly, the results
are consistent with the inhibition of the ZipA/FtsZ interaction
measured by FP and therefore indole 37 exhibited the best
profile of in vitro cell growth inhibition with MICs ranging
from 8–64 μg/mL.
Computational studies were also undertaken in an attempt to
identify new inhibitors of the interaction between ZipA and
FtsZ [90]. Utilizing the structure of the pyridylpyrimidine 34
(Figure 8) as a template, Rush et al. applied a shape-compari-
son program (rapid overlay of chemical structures, ROCS). This
study led to the identification of three lead-like scaffolds among
which compound 38 (Figure 8) was the most active with a Kd of
73.9 μM. In spite of the fact that this molecule was less active
than the original lead, the authors argued that it had less devel-
opment issues. Finally, in order to confirm the binding mode of
these new structures, the crystal structure of 39 (Kd = 83.1 μM)
in complex with ZipA was solved. Excitingly, the X-ray
analysis revealed that ROCS very accurately predicted the
binding mode and therefore validated its use as an alternative
approach to identify new promising leads as inhibitors of this
protein–protein interaction.
Despite the reported advances, these compounds were not found
to be therapeutically relevant inhibitors of the ZipA/FtsZ pro-
tein–protein interaction, nonetheless considering the challenges
involved in targeting PPIs, it is significant that the authors
demonstrated by NMR that compounds from this library bind to
ZipA at the FtsZ binding site and that small molecule disrup-
tors of the ZipA/FtsZ interaction could inhibit cell division in
both Gram-positive and Gram-negative microorganisms, find-
ings that could be of value in the development of optimized
antagonists for potential use as antibacterials.
N-Utilization substances (Nus) B and E
Another point of therapeutic intervention to develop new anti-
infectives that target cell viability is bacterial transcription, a
process that is executed by the enzyme RNA polymerase
(RNAP) and regulated by several transcription factors.
Similarly to the previously described targets, bacterial transcrip-
tion represents a promising antibacterial drug target for several
reasons: it is essential to cell viability, RNAP and its transcrip-
tion factors are considerably conserved across many important
bacterial strains and both of them differ from their eukaryotic
homologs [91,92].
The transcription factors NusB and NusE and their interaction is
vital for the efficient transcription in all bacteria [93] and have
recently attracted interest as a potential target for a new antibi-
otic class.
In 2017, McCluskey and co-workers carried out the virtual
screening of 56,000 compounds from the mini-Maybridge
library which led to the identification of five synthetically
accessible hits [94]. In order to validate these in silico screened
hits, their ability to inhibit the Bacillus subtilis NusB/NusE PPI
was examined. Gratifyingly, compounds 40 and 41 (Figure 9)
exhibited an inhibition of the NusB/NusE interaction at 25 μM
higher than 50% and IC50 values in the low micromolar range
(6.1 and 19.8 μM, respectively). A subsequent antibacterial
screening showed that the lead pyrimidine 40 was also a moder-
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Figure 9: Inhibitors of the NusB/NusE interaction.
ate inhibitor of the growth of the Gram-positive pathogen
B. subtilis and the Gram-negative microorganism E. coli.
The same research group developed further SAR studies using
compound 41 (Figure 9) as lead of interest [95]. To this end,
four focused compound libraries based on this bis-ether were
developed leading to the identification of the rigidified cis-
butene aminoguanidine analogue 42 (Figure 9) as both a good
inhibitor of the NusB/NusE PPI (>50% at 25 μM) and a potent
antibacterial against not only Gram-positive pathogens such as
methicillin-resistant S. aureus and S. pneumoniae but also
Gram-negative bacteria strains such as P. aeruginosa and
A. baumannii (MIC ≤ 3 μg/mL and ≤51 μg/mL, respectively)
[95]. In spite of the efficiency of the bis-aminoguanidine deriva-
tive 42, unfortunately, its toxicity was an issue. Nonetheless,
this study represents a step forward towards the potential devel-
opment of next-generation anti-transcription antibiotics and
validates the correlation between the NusB/NusE PPI and the in
vitro antibiotic effect.
The first specific inhibitor against S. aureus, including MRSA,
was reported very recently by Ma et al. [96]. After an in silico
screening of a combination of the previously mentioned mini-
Maybridge library and the Enamine antibacterial library, seven
hits were identified. Among all of them, the nitrophenol deriva-
tive MC4 (43, Figure 9) was able to inhibit NusB/NusE binding
with an IC50 of 34.7 μM. Its antimicrobial properties were also
evaluated against a panel of clinically relevant microorganisms
such as Enterococcus faecalis, Klebsiella pneumonia, Acineto-
bacter baumannii, Pseudomonas aeruginosa, Enterobacter
cloacae, Escherichia coli, Proteus vulgaris and Staphylococcus
aureus. However, in spite of the fact that NusB and NusE are
highly conserved in bacteria, the compound exhibited preferred
antibacterial activity against S. aureus strains (including
Beilstein J. Org. Chem. 2018, 14, 2881–2896.
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MRSA) with minimum inhibitory values as low as 8 μg/mL.
Pleasingly, unlike the aminoguanidine 42, compound 43 did not
display toxicity to mammalian cells.
Even though the NusB/NusE interaction is still in its infancy,
and further investigations are needed to both elucidate off-target
effects and apparent preferential inhibitory activity against
Gram-positive pathogens, the identification of promising small
molecules against these PPI (or other interactions involved in
bacterial transcription yet to be discovered and validated) may
have something to offer in the ongoing research towards the de-
velopment of new anti-infectives with novel mechanisms of
action.
Conclusion
Pathogenic bacteria are a leading cause of human mortality, par-
ticularly in Third World countries. Due to the fact that new
resistant microorganisms continue to emerge, combating these
infections has become a global challenge for which the
discovery and development of new antibacterial drugs is of crit-
ical importance.
Although progress has been made in order to address and over-
come drug resistance, there is an urgent need to develop new
antibacterial drug leads that operate through a novel mecha-
nism of action.
On the other hand, the past two decades have observed the
emergence of protein–protein interactions as a drug design
target. During this time, many important studies have been con-
ducted towards the identification and characterization of pro-
tein–protein interactions which have successfully resulted in
several modulators reaching the clinical stage (Figure 1). These
achievements would not have been possible without the utiliza-
tion of appropriate design and screening approaches to deter-
mine the interactions at a molecular level and hence the devel-
opment of PPIs as tractable targets.
To this end, interrogating interaction systems in prokaryotic
cells that are critical for bacterial survival have recently become
an attractive target which may offer therapeutically promising
perspectives for infectious diseases.
In this review, the most significant compounds which have been
found to disrupt protein–protein interactions in bacteria have
been highlighted. These chemical scaffolds target different bac-
terial processes such as replication (SSB and sliding clamp),
division (FtsZ) and transcription (NusB/NusE interaction). It is
hoped that the knowledge acquired in both discovering and
developing these inhibitors will lay the foundation for future
antibacterial drug development pipelines. Given that the pro-
tein interactions systems described are conserved in prokary-
otes but not present in eukaryotes, it may be feasible to develop
inhibitors that selectively target the microorganism systems, and
therefore avoiding mechanism-related side effects. However,
these large sets of interactions remain poorly characterized and
targeting them is a challenge.
Thus far, extensive in silico and high throughput screening
campaigns of libraries of compounds, combinatorial synthesis
and structure-based design approaches, biophysical screening
techniques (i.e., fluorescence polarization, surface plasmon
resonance and differential scanning fluorimetry) in combina-
tion with structural elucidation by combination of NMR and
X-ray crystallography have played a pivotal role in identifying
and deciphering the crucial target–inhibitor interactions with the
aim of treating disease.
Although this review covers the description of PPI in bacteria,
there are other strategies that are being explored towards the
discovery of new antibiotics with novel mechanisms of action
such as for example inhibitors of host–pathogen interactions
and of the type 3 secretion system (T3SS) in Gram-negative
bacteria, nonetheless, the specific targets remain unknown or
ambiguous [97,98].
The challenge for new drug discovery efforts in the field of
PPIs, which is still in the early stage, is to learn their real poten-
tial in combating infectious diseases. It is expected that en-
hanced understanding of the biology of bacteria and the nature
of the PPI interfaces, in combination with medicinal chemistry
efforts, may result in an opportunity to obtain antibacterial mol-
ecules whose mechanisms do not overlap with those of existing
anti-infective drugs and consequently reduce the burden of
multidrug-resistant pathogens.
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